Abstract KLLN is a p53 target gene with DNA binding function and represents a highly plausible candidate breast cancer predisposition gene. We screened for predisposing variants in 860 high-risk breast cancer families using high resolution melt analysis. A germline c.339_340delAG variant predicted to cause premature termination of the protein after 57 alternative amino acid residues was identified in 3/860 families who tested negative for BRCA1 and BRCA2 mutations and in 1/84 sporadic breast cancer cases.
Introduction
The genetic cause of multiple-case breast cancer or breast/ ovarian cancer families has only been elucidated in approximately one-third of families, with the majority of these explained by germline BRCA1 or BRCA2 mutations [1] . Additional moderate-or low-penetrance variants have been identified in genes such as ATM or CHEK2, but it is likely that additional gene variants contribute to the apparently highly penetrant genetic predisposition observed in many breast cancer kindreds negative for mutations in known predisposition genes.
KILLIN is a 20 kDa nuclear protein that is necessary for p53-induced apoptosis [2] . In addition, germline methylation of the KLLN promoter has been associated with an increased risk of breast and renal cancer in Cowden syndrome and Cowden syndrome-like individuals [3] , providing a substantial biological basis for considering KLLN as a breast cancer predisposition gene. We screened for germline variants in the KLLN gene in multiple-case breast cancer families to assess this possibility. This is the first study to analyze the relationship of this gene to breast cancer risk.
Materials and methods

Sample cohorts
Multiple-case breast cancer families were selected from the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), which recruits families from Familial Cancer Clinics in Australia and New Zealand [1] . An index case from each family was previously screened for mutations in BRCA1 and BRCA2 including for large deletions.
Additional breast cancer cases with features of a germline predisposition (age of onset under the age of 40, a family history of breast cancer (defined as two or more cases of breast cancer in first or second degree relatives) or bilateral breast cancer irrespective of age of onset or family history) were provided by Dr. Diana Eccles from patients presenting to hospitals in the south of England [4] . Sporadic breast cancers were provided by the Peter MacCallum Cancer Centre tissue bank or by Dr Nick Hayward (Queensland Institute for Medical Research, Brisbane, Australia). Unselected ovarian cancer cases were obtained from patients presenting to hospitals in the south of England, UK [5] .
Non-cancer control DNA samples were obtained from kConFab (age-and ethnicity-matched best friend controls) and from the Princess Anne Hospital, Southampton, UK [6] .
Variant screening by high resolution melt (HRM) analysis
Oligonucleotide primers were designed using AmplifX v 1.5.4 (http://ifrjr.nord.univ-mrs.fr/AmplifX) and Primer3 [7] to amplify the coding region of the KLLN gene (NM_0011126049.1) in four overlapping fragments (Table 1) . DNA samples for HRM were whole genome amplified using RepliG according to the manufacturer's instructions (Qiagen, Hilden, Germany). HRM analysis and DNA resequencing were performed as described previously [8] . All samples with variant HRM profiles were reamplified from non-whole genome amplified DNA and Sanger sequenced.
Analysis of loss of heterozygosity (LOH)
Epithelial tumor cells were needle microdissected from 10 lm sections of formalin-fixed paraffin embedded tissue and DNA was extracted as previously described [9] . The variant of interest was PCR amplified and sequenced as above. LOH was estimated based on the intensity of the variant nucleotide relative to the normal nucleotide in the sequence electrophoretogram.
Results
We screened the entire KLLN coding region for germline variants in 556 individuals from 460 multiple-case breast cancer families with no known pathogenic mutations in BRCA1 or BRCA2 from the Australasian kConFab cohort using HRM. We identified five non-synonymous sequence variants and one indel (Tables 2, 3 ). The latter variant, a 2 bp frame shifting deletion, c.339_340delAG, was observed in three families and is predicted to lead to alteration of the C-terminal of the protein with 57 novel amino acids substituted from residue 114 prior to premature termination [p.(Ala115Serfs*58)].
We screened for the c.339_340delAG variant in a number of other cohorts. It was observed in one sporadic breast cancer case (1/84, 1.2 %) but not in the index cases of an additional 399 breast cancer families from kConFab or 379 individuals diagnosed with breast cancer selected on the basis of: age of onset under the age of 40, a family history of breast cancer or bilateral breast cancer Southampton controls 0/237 a n = 32 tumor DNA only analyzed b n = 9 tumor DNA only analyzed irrespective of age of onset or family history [4] . The variant was also observed in non-cancer controls at a similar frequency (2/463, 0.4%), and also in 2/182 families (1.1%) known to carry BRCA1 or BRCA2 mutations. As the genetic basis of breast and ovarian cancer is sometimes shared in families, we also assessed a cohort of unselected ovarian cancers, but no germline or somatic mutations were detected in any of these cases (n = 108). Classic tumor suppressor genes such as BRCA1 are very frequently associated with bi-allelic inactivation in tumors, consistent with the ''two-hit hypothesis'' [10] . LOH, where the wild-type allele is lost in the tumor, is one mechanism whereby cancer cells acquire bi-allelic inactivation of a tumor suppressor [11] . We sequenced the full KLLN gene in two available tumors from different individuals from the same family who both carried the c.339_340delAG variant (2202 and 2191). Both tumors showed clear loss of the variant allele and retention of the wild-type allele (Fig. 1) . No inactivating somatic mutations were identified in the retained allele in these cases.
We tested the predicted effect of the five non-synonymous variants using SIFT [12] , PolyPhen-2 [13] , MutPred [14] , PMUT [15] , MutationTaster [16] , and SNAP [17] . P.Gly44Arg was predicted to have a damaging effect in 4/6 of these in silico prediction tools (Table 3) ; however, this variant has been observed in the 1,000 Genomes project [18] and in Asian populations at a frequency of *1 % [19] . One of two linked variants, p.Trp149Arg, was called deleterious in 2/6 predictors, but both this and the linked p.Asn131Ser allele were previously identified as polymorphisms. The other two variants, p.Cys99Trp and p.Pro104Ser were predicted to be damaging in 1/6 and 2/6 algorithms, respectively. These variants were screened in our control cohorts but were not observed.
Discussion
KILLIN is a 178 amino acid residue protein that was identified through a screen for p53 target genes [2] . It functions as a DNA binding protein that is thought to cause stalled replication forks and thus S-phase arrest, and is essential for p53-mediated apoptosis. Accordingly, KILLIN represents a novel mechanism of p53 arrest distinct from p21-mediated G1 arrest, and one that is linked to apoptosis. While the mechanism for KILLIN-mediated apoptosis is not entirely elucidated, it is thought to be connected to the DNA damage response pathway, including CHK1 and the breast cancer predisposition gene CHK2. Thus, KLLN represents a highly plausible candidate breast cancer tumor suppressor, as it intersects with the key hereditary predisposition pathway of DNA damage and repair. We identified a likely inactivating mutation in KLLN in multiple-case breast cancer families that was predicted to alter the C-terminal portion of the protein after residue 114. However, functional domain mapping of the KILLIN protein suggested that only amino acid residues 8-49 are required for induction of apoptosis and the critical DNA binding activity [2] . Thus, in spite of the predicted disruption of the final third of the protein, the c.339_340de-lAG variant may still provide functional KILLIN protein.
We sought further genetic evidence for KLLN as a breast cancer predisposition gene by analyzing for the frameshift variant in several cohorts of individuals, including multiple-case breast and breast/ovarian cancer families, nonfamilial breast cancer including an early age-of-onset group, non-familial ovarian cancer and two control cohorts. Additional individuals carrying the c.339_340delAG variant were found at a low frequency (0-1.2 %). However, the frequency of the c.339_340delAG variant was similar in the cancer and control groups (*0.5 %) and was also detected in two families where known pathogenic mutations in BRCA2 explained all affected individuals in each pedigree. In addition, the analysis of LOH in two available tumor samples indicated that the wild-type allele was retained in both cases, contrary to the expectation of biallelic inactivation. Thus, it appears very unlikely that the c.339_340delAG variant in KLLN is a high-penetrance tumor suppressor allele. In addition, despite analysis of a large number of index cases from breast cancer families, no other deleterious mutations were identified suggesting that the KLLN is unlikely to play a significant role in high-risk breast cancer families. Conflicts of interest The authors declare no conflicts of interest.
